Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy

Urology

Volumn 49, Issue 6, 1997, Pages 887-893

  Cookson, Michael S ^a   Fleshner, Neil E ^a   Soloway, Scott M ^a   Fair, William R ^a  

^a Division of Urology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURGERY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; TRANSURETHRAL RESECTION; TREATMENT PLANNING; TUMOR CLASSIFICATION;

ADULT; AGED; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PALPATION; PREOPERATIVE CARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0030926567     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00107-6     Document Type: Article

References (18)

1. Parker SL, Tong T, Bolden, Wingo PA. Cancer statistics, 1997. CA. 47:1997;5-27.
2. Mettlin C, Jones GW, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer related check-up: prostate and endometrial cancer. CA. 43:1993;42-46.
3. Slawin KM, Ohori M, Dillioglugil O, Scardino PT. Screening for prostate cancer: an analysis of the early experience. CA. 45:1995;134-145.
4. Olsson CA, Goluboff ET. Detection and treatment of prostate cancer: perspective of the urologist. J Urol. 152:1994;1695-1699.
5. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol. 152:1994;1732-1736.
6. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate. 4:1992;129-138. (suppl).
7. Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-detected (clinical stage T1c or B0) prostate cancer. Urol Clin North Am. 20:1993;687-693.
8. Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, Oesterling JE. Clinical stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology. 41:1993;3-8.
9. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins Experience with tumors found on transurethral resection (stages T1a and T1b) and on needle biopsy (stage T1c). J Urol. 152:1994;1721-1729.
10. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 152:1994;1714-1720.
11. Scaletsky R, Koch MO, Eckstein CW, Bicknell SL, Gray GF Jr, Smith JA. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. J Urol. 152:1994;129-131.
12. Matthews GW, Fracchia JA. PSA-detected prostate cancer: contrasts with palpable disease. J Surg Oncol. 59:1995;28-30.
13. Lerner SE, Seay TM, Blute ML, Bergstrahl EJ, Barrett D, Zincke H. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol. 155:1996;821-826.
14. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 271:1994;368-374.
15. Catalona WJ, Richie JP, Ahman FR, Hudson M, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 151:1994;1283-1290.
16. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen. J Urol. 155:1996;816-820.
17. Metlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, Mostofi FK. J Urol. 152:1994;1737-1740.
18. Catalona WJ, Smith DS, Ratliff TL, Basker JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening. JAMA. 270:1993;948-954.